MedicaidPrior AuthMedium impact
KMAP BULLETIN: Pharmaceutical Prior Authorization Updates – March 2026
Kansas Medicaid (KanCare)·KS · Hematology, Oncology, Cardiology +2 more·Provider Bulletin
Effective date
Apr 1, 2026
We identified it
Jun 21, 2026
Summary
Effective April 1, 2026, eight specific medications including Concizumab-mtci (Alhemo®), Dabigatran (Pradaxa®) Packets, and six others will require Preferred Drug List Prior Authorization for Kansas Medicaid (KMAP). This affects billing for these medications as prior authorization will be mandatory before administration or prescription.
Action Required
By April 1, 2026: Billing team must update prior authorization requirements for the following medications: Concizumab-mtci (Alhemo®), Dabigatran (Pradaxa®) Packets, Filgrastim-txid (Nypozi™), Fitusiran (Qfitlia™), Hydroxyurea (Siklos®), Hydroxyurea (Xromi®), Marstacimab-hncq (Hympavzi®), and Olezarsen (Tryngolza®). Providers must obtain PDL prior authorization before prescribing or administering these medications to Kansas Medicaid patients. Update EMR alerts and pharmacy ordering systems to flag these medications. Monitor KanCare MCO implementation dates as they may vary from April 1st.